Here we describe a protocol to dissect the peroxisomal matrix protein import pathway using a cell-free in vitro system. the system relies on a postnuclear supernatant (pns), which is prepared from rat/mouse liver, to act as a source of peroxisomes and cytosolic components. a typical in vitro assay comprises the following steps: (i) incubation of the pns with an in vitro-synthesized 35 s-labeled reporter protein; (ii) treatment of the organelle suspension with a protease that degrades reporter proteins that have not associated with peroxisomes; and (iii) sDs-paGe/autoradiography analysis. to study transport of proteins into peroxisomes, it is possible to use organelle-resident proteins that contain a peroxisomal targeting signal (pts) as reporters in the assay. In addition, a receptor (peX5l/s or peX5l.peX7) can be used to report the dynamics of shuttling proteins that mediate the import process. thus, different but complementary perspectives on the mechanism of this pathway can be obtained. We also describe strategies to fortify the system with recombinant proteins to increase import yields and block specific parts of the machinery at a number of steps. the system recapitulates all the steps of the pathway, including mono-ubiquitination of peX5l/s at the peroxisome membrane and its atp-dependent export back into the cytosol by peX1/peX6. an in vitro import(/export) experiment can be completed in 24 h.
IntroDuctIon
In their basic configuration, cell-free organelle-based in vitro protein import assays comprise three steps: (i) incubation of an organelle suspension with an in vitro-synthesized 35 S-labeled reporter protein harboring a specific targeting sequence; (ii) treatment of the organelle suspension with a vast amount of an aggressive protease to degrade the nonimported reporter protein; and (iii) analysis of organelle proteins by SDS-PAGE/autoradiography. The experimental simplicity of these assays-together with the fact that they use a completely open experimental system (meaning that components can be added or removed in an expedited manner) -are the reasons why they have been in use for so many decades, yielding a wealth of information about how mitochondria, chloroplasts, endoplasmic reticula and peroxisomes import their proteins [1] [2] [3] [4] .
The application of this technique to the study of the peroxisomal matrix protein import machinery (PIM) has been particularly informative because of the variety of reporter proteins that can be used in these assays. Indeed, besides organelle-resident proteins that contain a type 1 or type 2 PTS (Fig. 1a) , it is also possible to use the corresponding shuttling receptors PEX5L/S (peroxisomal biogenesis factor 5) and the protein complex PEX5L-PEX7 as reporter proteins (see Fig. 1b for an overview of the peroxisomal matrix import machinery). Note that there are two main isoforms of PEX5: PEX5L and PEX5S; for simplicity we omit the L/S whenever a statement applies to both (Fig. 1a) . Thus, different but complementary perspectives on the PIM, each centered on a different component, can be obtained.
Here we present a detailed protocol to perform these assays, as well as several strategies to block the peroxisomal matrix protein import pathway at virtually any step. The protocol provided uses a PNS from mouse or rat liver as a source of peroxisomes and cytosolic components, but other sources (e.g., cultured cells) can also be used. Besides an in vitro-synthesized 35 S-labeled reporter protein, some common biochemical reagents and protein analysis equipment, only a few easy-to-obtain recombinant proteins are necessary to perform these assays.
Development of the protocol
Despite their simplicity and the large amounts of mechanistic data they can potentially generate, in vitro protein import systems were not very popular in the peroxisomal protein sorting field for many years. A major problem was the low import yields obtained with many of the reporter proteins tested in the early attempts [5] [6] [7] [8] [9] . This, together with a lack of bona fide negative controls, made the interpretation of those experiments a difficult task.
Two main reasons explain why peroxisomes yielded poor results when used in in vitro protein import assays with 35 S-labeled matrix proteins as reporters. The first is related to the fact that the PIM is largely partitioned between the peroxisomal membrane and the cytosol. PIM components found mainly in the cytosol include the low-abundance proteins PEX5 and PEX7, as well as components of the ubiquitin cascade ( Fig. 1b; refs. [10] [11] [12] . This, together with the fact that neither the shuttling receptors PEX5L/S nor PEX7 are present in the rabbit reticulocyte lysate (RRL) 13, 14 -the system generally used to synthesize 35 S-labeled proteins-means that any attempt to use purified peroxisomes or even crude organelle fractions in in vitro import assays programmed with 35 S-labeled peroxisomal matrix proteins was poised to produce poor results.
The second reason stems from the fragility of peroxisomes and from the fact that the PTS1 present in the vast majority of peroxisomal matrix proteins is not cleaved upon import 15, 16 . Thus, peroxisome suspensions (e.g., a PNS or a highly purified peroxisome fraction) are always contaminated with soluble PTS1-containing proteins that have leaked from the organelles during tissue homogenization or simple manipulations such as organelle pelleting and resuspension procedures 15, 17 . This creates competition phenomena between the 35 S-labeled reporter protein (be it a PTS1 protein or a PTS2 protein) and the endogenous A cell-free organelle-based in vitro system for studying the peroxisomal protein import machinery PTS1 proteins at two critical steps: (i) the interaction with the endogenous shuttling receptor PEX5 and (ii) the interaction of the cargo protein-PEX5 complexes with the docking/translocation machinery (DTM; Fig. 1b) .
Almost paradoxically, the reasons behind the poor performance of peroxisomes in in vitro import assays containing 35 S-labeled peroxisomal matrix proteins are also those behind the robustness and specificity of the PNS-based PEX5-centered in vitro assay, the first of the four in vitro systems described here to be developed 18 . Indeed, the low abundance of endogenous PEX5 in PNS, as well as the presence of soluble import-competent PTS1 proteins in these supernatants implies, on the one hand, that the few nanograms of 35 S-labeled PEX5 protein that are generally used in in vitro assays will not face much competition from the endogenous receptor. On the other hand, the 35 S-labeled protein can interact with endogenous PTS1 proteins, thus yielding the correct substrate for the DTM 19 . Thus, a relatively large fraction of the 35 S-labeled PEX5 added to these assays engages in protein transport to the peroxisome. This, together with the easily detectable biochemical alterations that PEX5 undergoes during its transient passage through the peroxisome (i.e., acquisition of a protease-protected status and mono-ubiquitination; 20, 21 ), makes the PEX5-centered in vitro assay one of the most useful and informative tools for studying the PIM [22] [23] [24] [25] .
In contrast to the PEX5-centered in vitro assay, which requires nothing besides the components provided by a PNS and a few chemicals, all the other assays, namely the PEX7-, the PTS2-and the PTS1-centered in vitro systems, require some modifications to the basic protocol. We note that all these modifications are extremely simple, but they do increase in a marked way the PTS1 is a small C-terminal peptide, usually ending in S-K-L 16 . PTS2 is a degenerated nonapeptide present at the N termini of a few peroxisomal proteins, which-contrary to PTS1-is cleaved upon import 46, 47 . The PEX5 transcript undergoes alternative splicing, yielding a small and a large isoform, PEX5S and PEX5L, respectively 45 . The first isoform does not interact with PEX7/PTS2 and thus participates only in the PTS1-mediated protein import pathway; the second isoform transports both types of cargo proteins to the peroxisome 45, 48 . (b) The mechanism of the PIM. Cytosolic PEX5 (stage 0 PEX5) forms a complex with newly synthesized matrix proteins (CP; stage 1a). The receptor-cargo complex then docks at the peroxisomal membrane docking/translocation machinery (DTM; stage 1b), where it is inserted (stage 2), resulting in the release of the cargo protein into the organelle matrix. PEX5 is then mono-ubiquitinated at cysteine 11 (stage 3a), recognized by the receptor export module (REM; stage 3b) and extracted in an ATP-dependent step, yielding cytosolic mono-ubiquitinated PEX5 (stage 4). Finally, the ubiquitin moiety is removed, probably by a combination of enzymatic (USP9X) and nonenzymatic events (e.g., by nucleophiles such as GSH), yielding free PEX5 (stage 0). PEX7, the coreceptor for PTS2 proteins, remains bound to PEX5 during most of the steps of the PTS2-mediated protein import pathway. For simplicity, PEX7 is not shown in the figure. Several strategies/tools to block this pathway at different steps (shown in red; ) are also indicated. ATPγS, adenosine 5'[γ-thio]triphosphate; C11S/A, PEX5 protein-mutated version with the conserved cysteine 11 replaced by a serine or an alanine residue; CP, cargo protein; cyt, cytosol; DTM, docking/translocation module; E1, ubiquitin-activating enzyme; E2, ubiquitin-conjugating enzyme; GSH, glutathione; GST-Ub, glutathione S-transferase ubiquitin fusion protein; IAA, iodoacetamide; NDPEX14, recombinant protein comprising the soluble N-terminal domain of PEX14; Pi, inorganic phosphate; PPi, pyrophosphate; REM, receptor export module; mat, peroxisomal matrix; T, temperature; TPR, recombinant protein comprising only the PEX5 tetratricopeptide repeat domain; Ub, ubiquitin; Ubal, ubiquitin aldehyde.
robustness, and thus the specificity, of these assays. The strategy to increase the import yields of PTS2 proteins from essentially 0 to 5-10% of the input reporter protein consists of fortifying the PNS with a recombinant mutant PEX5L protein (e.g., ∆C1PEX5L) that still harbors all the domains necessary to interact with the DTM and with the PEX7/PTS2 heterodimer but that is no longer competent in transporting PTS1 proteins to the organelle 26 . In this way, the concentration of competent PEX5L species in the PTS2-mediated protein import pathway is increased (thus compensating for the unavoidable dilution of the low-abundance endogenous PEX5L protein in the assays) without raising the concentrations of protein complexes comprising PEX5 and endogenous PTS1 proteins, which would compete with the PTS2 reporter protein at the DTM level.
A similar fortification strategy is used in the PEX7-centered in vitro assays. Here, supplementation of the PNS with recombinant ∆C1PEX5L markedly increases the fraction of 35 S-labeled PEX7 that targets the peroxisome, but even better results are obtained when both ∆C1PEX5L and a recombinant PTS2 protein, the precursor of phytanoyl-CoA hydroxylase (prePHYH), are added to the PNS 3 . It should also be noted that the ∆C1PEX5L.PEX7.prePHYH trimeric complex is extremely stable (half-life of 3 h). Thus, for some specific purposes it may be advantageous to preassemble the trimeric complex in vitro before starting the import/export assay 13 .
Although endogenous PEX5 is surely a limiting factor in the PTS1-centered in vitro assays as well, fortifying the PNS with recombinant PEX5 has either no effect or increases the import yields by only a twofold factor, depending on the reporter PTS1 protein. The presence of large amounts of endogenous soluble PTS1 proteins in the PNS explains this phenomenon. As the concentration of PEX5 in the assay is increased, so is the concentration of complexes comprising endogenous PTS1 proteins and PEX5, thus titrating the available DTMs. However, we have recently found that, for some reporter PTS1 proteins, this problem can be circumvented. Indeed, preincubation of 35 S-labeled 2,4-dienoyl-CoA reductase or sterol carrier protein x (SCPx) with a few nanograms of recombinant PEX5 before starting the import assay markedly improves in vitro import yields 27 . In the case of SCPx, this effect is particularly strong, as import of this protein becomes almost completely dependent on the recombinant PEX5 with which it is preincubated. Although we are still lacking detailed data on the PEX5-SCPx interaction, this suggests that this protein complex is particularly stable, which is supported by previous data on the interaction between the C-terminal half of PEX5 and SCP2, a protein identical to the C-terminal fourth of SCPx 28 . Thus, by starting the import assays with a preassembled PEX5-SCPx complex, competition between the 35 S-labeled protein and endogenous PTS1 proteins for PEX5 binding is avoided. Furthermore, because the amount of recombinant PEX5 used in the preincubation step that is carried over to the in vitro import assay is small, the DTM titration problem referred to above is also avoided.
Applications of the method
The organelle-based in vitro assays described here reproduce all the steps of the peroxisomal matrix protein import pathway. These include the following: (i) transport of newly synthesized proteins into the peroxisome matrix 13, 14, 26, 27 , (ii) mono-ubiquitination of PEX5 at the peroxisomal DTM 21, 29 , (iii) extraction of mono-ubiquitinated PEX5 from the DTM into the cytosol by PEX1/PEX6 (refs. 17,22,25) and (iv) deubiquitination of PEX5 in the cytosol 23, 30, 31 . Thus, within a single biological pathway, which can be fully recapitulated in vitro, several different subjects can be addressed, namely protein translocation across biological membranes, RING (really interesting new gene) E3s and protein ubiquitination/deubiquitination, and mechanoenzymes of the AAA (ATPases associated with diverse cellular activities) family. Given the increasing numbers of tools and strategies that can be used to block this pathway at virtually any step ( Table 1) , it is clear that this experimental system will continue to provide valuable insights into the molecular mechanisms of all this machinery, similarly to what has been seen with all in vitro systems that have been used to study protein sorting to other organelles 1, 2, 4 .
The protocol presented here uses postnuclear supernatants from rat/mouse liver as a source of peroxisomes and cytosolic components (Box 1). There are two reasons behind this option: (i) peroxisomes are quite abundant in this organ 32 and (ii) a PNS prepared from the liver of a single animal is sufficient to keep several researchers performing daily assays for several months. However, if necessary, PNS prepared from cultured cells can also be used, as described before for human skin fibroblasts from control individuals and Zellweger patients, CHO and HeLa cells 22, 33, 34 . Thus, the protocol and experimental strategies that are presented here can potentially be applied to a variety of other cells (e.g., mouse embryonic fibroblasts) with minor or no adaptations.
Finally, it may be important to note that although we find it particularly convenient to use 35 S-labeled reporter proteins in these assays (authentic/untagged reporter proteins can be used; the results are obtained by a simple autoradiography, which is semiquantitative in nature; and mammalian reporter proteins synthesized in a RRL tend to be fully soluble/active), a western blot/immunodetection procedure can also be used to monitor these assays, as previously shown for endogenous rat liver PEX5 (refs. 17,18) and, more recently, for a recombinant tagged version of Arabidopsis thaliana PEX5 (ref. 24) . The use of epitope-tagged reporter proteins in these assays is particularly promising because it may also facilitate future attempts to scale up these assays for more quantitatively demanding purposes, such as structural studies of the DTM.
Comparison with other methods
Besides organelle-based in vitro assays, only one other type of in vitro assay is currently available for studying the PIM. This comprises cell-based assays that use semipermeabilized cultured cells as a source of peroxisomes [35] [36] [37] . In brief, cells are semipermeabilized, either mechanically or by treatment with substances that partially solubilize the plasma membrane (e.g., streptolysin O); incubated with a reporter protein; and analyzed by (immuno)fluorescence microscopy. In one case, an ELISA-based detection method was coupled to the import assay to better assess the import efficiency of the reporter protein 37 .
There are advantages and disadvantages associated with such cell-based assays. The latter include the requirement of a continuous supply of live cells and the need to use reporter proteins that have to be chemically different from any other protein that is already present in the semipermeabilized cells (otherwise, it would be difficult to distinguish a reporter protein from its endogenous pool). A major advantage of such assays resides in the fact that the methods used to prepare semipermeabilized cells are very gentle and include a washing of the cells just before the import assays. Thus, there are no soluble endogenous PTS1 proteins competing with PTS1 or PTS2 reporter proteins 14, 27 . Concentration in the assay should be titrated for each PTS1 reporter cargo protein. Preincubation of recombinant PEX5 with some PTS1 proteins markedly increases their import yields
∆C1PEX5L
A protein comprising the first 324 amino acid residues of PEX5L. It contains all the domains necessary to interact with PEX7/PTS2 and the DTM, but it does not interact efficiently with PTS1 proteins 19, 50 . Supplementing import reactions with recombinant ∆C1PEX5L boosts the PTS2-mediated import pathway. It bypasses competition with endogenous PTS1-containing proteins 3, 26 PEX5L(N526K) Full-length PEX5L containing the mutation N526K. This protein cannot bind PTS1 proteins efficiently, but, like ∆C1PEX5L, it is competent in the PTS2-mediated protein import pathway 51, 52 . Supplementing import reactions with recombinant PEX5L(N526K) boosts the PTS2-mediated import 3, 26 TPRs C-terminal half of PEX5 (amino acids 315-639 of PEX5L) comprising its tetratricopeptide-repeat domain, which is necessary for efficient PTS1 cargo binding 52 . It is import-incompetent because it lacks the N-terminal domains required for interaction with the DTM 53 . The recombinant protein is used to sequester both 35 S-labeled and endogenous PTS1-containing proteins. Thus, it blocks both import of PTS1 reporter proteins and the PTS1-mediated insertion of 35 S-labeled PEX5 into the DTM 19, 27, 54 .
Full-length PEX5L in which cysteine 11 has been replaced by a serine or an alanine, respectively. These mutant PEX5L species can promote one cycle of protein transport to the peroxisome matrix. However, they are export-incompetent because they cannot be mono-ubiquitinated efficiently. Thus, they accumulate at the DTM 21, 23 PEX5L(C11K) Full-length PEX5L in which cysteine 11 has been replaced by lysine. This protein is functional in both the import and export steps. Mono-ubiquitination at the lysine residue yields an isopeptide bond, which is much more stable than the thioester bond linking ubiquitin to the cysteine residue in wild-type PEX5L. Thus, SDS-PAGE can be performed under reducing conditions 23 PEX5L-EGFP Full-length PEX5L with a C-terminal EGFP tag. This bulky PEX5 fusion protein becomes inserted into the DTM and is mono-ubiquitinated. However, although mono-ubiquitinated PEX5L-EGFP is recognized by the REM, it is not efficiently released into the cytosol. A partially dislocated species accumulates in in vitro assays 55 
NDPEX14
Recombinant protein comprising the first 80 amino acid residues of human PEX14, a component of the DTM 56 . This domain binds with high affinity the diaromatic motifs present in the N-terminal half of PEX5, which are essential for PEX5 function 57, 58 . Used to inhibit import of all cargoes and insertion of the corresponding receptors into the DTM 3, 27 PrePHYH Recombinant precursor of phytanoyl-CoA hydroxylase, a PTS2 protein used to stimulate targeting of PEX7 to the peroxisome 3, 13 Import at <16 °C PEX5-cargo protein complexes dock at the DTM, but insertion of PEX5 into the DTM and cargo translocation are inhibited 27 Import at 16<T<26 °C Insertion of PEX5 into the DTM and cargo-translocation occur at these temperatures, but the ubiquitin conjugating cascade is compromised. Thus, PEX5 export is greatly diminished and thus more PEX5 is detected at the DTM 27, 59 Apyrase Apyrase is an ATP-diphosphatase that hydrolyzes ATP and other NTPs 60 , effectively blocking PEX5 mono-ubiquitination and export 26 . PEX5 will accumulate at the DTM. Pretreat both the lysate and the ATP-primed PNS mix with 5-20 U/ml for 2 min at 37 °C Iodoacetamide Iodoacetamide is an alkylating agent that modifies cysteine 11 of PEX5 54 . Alkylated PEX5 cannot be mono-ubiquitinated and, consequently, the receptor accumulates at the DTM ATPγS/ AMP-PNP Nonhydrolyzable ATP analogs such as ATPγS or AMP-PNP are excellent substrates for the ubiquitin-activating enzyme 61 . Thus, PEX5 mono-ubiquitination occurs normally in the presence of these nucleotides. However, they inhibit the AAA ATPases that comprise the REM and thus Ub-PEX5 becomes trapped at the DTM 21, 30 GST-Ub GST-Ub is a recombinant fusion protein comprising glutathione S-transferase and ubiquitin. This molecule is efficiently used by the ubiquitin-conjugating cascade and can be coupled to cysteine 11 of PEX5. However, it acts as a dominantnegative analog of ubiquitin, completely blocking export of mono-ubiquitinated PEX5 from the DTM 21 Ubal Ubiquitin aldehyde is a ubiquitin in which the C-terminal glycine carboxyl group has been synthetically modified to an aldehyde 62 . It is a potent and highly specific inhibitor of most deubiquitinases, including USP9X, the enzyme that acts on cytosolic Ub-PEX5 (note that DTM-embedded Ub-PEX5 is not a substrate for deubiquitinases) 30 . Use at 1-2 µM in such assays. This is probably the reason why cell-based in vitro import assays, in contrast to the organelle-based assays described here, can be used to study the import pathway of proteins harboring a weak PTS1 (e.g., catalase 36 ).
Experimental design
Organelle-based in vitro assays are very simple and quick to perform. Preparation of some reagents can consume a few days, but as all these can be stored frozen for many months (e.g., the PNS and recombinant proteins) or even years (e.g., plasmids encoding the reporter proteins for in vitro transcription/translation), this part of the work is seldom performed. With the exception of the reduced glutathione and N-ethylmaleimide (NEM) solutions, which are freshly prepared, all reagents are kept at 4 °C or stored in small aliquots at either −20 or −70 °C and thawed just before starting the in vitro assay. When performing this type of assay, it is important to know that when any protein is incubated with an organelle suspension, a fraction of it will always be recovered together with the organelles upon centrifugation (e.g., ref. 38) . The fraction of the protein that sediments with the organelles may simply reflect the amount of supernatant that is always entrapped in the organelle pellet, or may in fact be larger if the protein has some tendency to aggregate or to interact nonspecifically with organelle membranes. If, in addition to this phenomenon, one also considers that some proteins may be intrinsically protease-resistant, then it is easy to understand why improperly controlled experiments can provide deceiving conclusions.
The protocol presented here provides a number of independent strategies that efficiently block protein import/export into/from peroxisomes (i.e., negative controls), and thus any unspecific phenomena, such as the ones described above, will be easily identified. For instance, addition of recombinant NDPEX14 ( Table 1) to an import assay completely blocks the PEX5-, PEX7-, PTS1-and PTS2-centered in vitro assays, whereas the addition of a vast excess of recombinant prePHYH to an in vitro assay programmed with an 35 S-labeled PTS2 protein will block (compete with) import of the reporter protein without blocking insertion of PEX7 into the peroxisomal DTM. Likewise, addition of a recombinant protein comprising the PTS1-binding domain of PEX5 (referred to as a TPR; see Table 1 ) to a PEX5-centered in vitro assay, or its presence in the preincubation mixture containing 35 S-labeled SCPx and recombinant PEX5, will block the PTS1-dependent insertion of 35 S-labeled PEX5 into the DTM or peroxisomal import of 35 S-labeled SCPx, respectively.
Another frequently used strategy to ensure that an in vitro assay is working properly consists of assessing the amounts of reporter protein that acquire an organelle-associated, protease-protected status in a time-and temperature-dependent manner. Naturally, after protease treatment no reporter protein should be detected in organelles at the 0-min time point, and the same result should be obtained when the in vitro assay is performed at 0-4 °C because insertion of receptor-cargo protein complexes into the DTM does not occur at this temperature 26, 27 . Although these experiments should not be taken as true negative controls (artifacts may also be time-and/or temperature-dependent), an unexpected result (e.g., 'import' in a 0-4 °C sample) indicates the existence of problems with either the reporter protein or the proteolysis conditions.
The experimental conditions used here in the protease-treatment step are rather harsh: 500-600 µg of total PNS protein containing 1-2 µl of a RRL in a 100-µl volume is treated with 40 µg of an aggressive protease (e.g., proteinase K (PK) or pronase) for 30-45 min on ice. For the reporter proteins used here, these conditions are far in excess of those required to completely degrade the soluble 35 S-labeled proteins under identical conditions. However, this is not necessarily true for other proteins, many of which are actually peroxisomal matrix proteins. Thus, when using a reporter protein for the first time, its intrinsic susceptibility to aggressive proteases has to be determined. This is easily done by incubating 0.5-to 1-µl aliquots of the RRL containing the 35 S-labeled protein with different concentrations of a protease (e.g., PK, pronase or trypsin) in 100 µl of import buffer, and following Steps 6B(ii), 6A(iv) and 7-11 of the main protocol. Samples are then analyzed by SDS-PAGE/ western blotting/autoradiography, as described (Box 2).
Once the robustness and specificity of the in vitro assays are established, many different tools/strategies can be used to block the PIM at different steps. Some of these are as simple as decreasing the temperature of the assays, or adding nonhydrolyzable ATP analogs, whereas others require mutant versions of the recombinant
Box 1 | Preparation of rat/mouse liver PNS • tIMInG ~1 h
 crItIcal Ensure that all materials and solutions are ice-cold. 1. Euthanize one rat/mouse and immediately open the abdominal cavity using scissors. ! cautIon Experiments using rodents must conform to national and institutional regulations. 2. Collect the liver and wash it with ice-cold SEM buffer. Blot it briefly on paper towels, and weigh it. 3. Put the liver in a Petri dish standing on ice and cut it into small pieces using scissors. 4. Transfer the liver pieces to the ice-cold Potter-Elvehjem glass tube and add a total of 4 ml of ice-cold SEM buffer (supplemented with a 1:200 (vol/vol) E-64 stock solution) per gram of liver. 5. Homogenize the liver with 1-2 strokes of the Teflon pestle working at 600 r.p.m.  crItIcal step Only 1-2 strokes are used, in order to minimize organelle disruption. 6. Transfer the total homogenate to a centrifuge tube (e.g., for rotor SS-34) and centrifuge at 600g for 10 min at 4 °C. Transfer the supernatant to a clean centrifuge tube precooled on ice, and repeat the centrifugation step. The supernatant of this last centrifugation is the PNS. 7. Snap-freeze single-use aliquots (e.g., 100-200 µl in microtubes) in liquid N 2 and store them at −70 °C. ! cautIon When handling liquid nitrogen, always use personal protective equipment, including insulated leather gloves and eye and face protection.  pause poInt When stored at −70 °C, the PNS remains active for many months. 8. Determine the protein concentration of the PNS (e.g., using the Bradford method). It should be ~40-90 µg/µl. or 35 S-labeled proteins mentioned here. A summary of all the tools/strategies currently used is presented in Table 1 .
Limitations
The PEX5-, PEX7-and PTS2-centered in vitro assays are all very robust. However, the PTS1-centered in vitro system still presents some limitations. Indeed, not all PTS1-containing cargo proteins can be used in these assays. For instance, proteins such as catalase, alanine glyoxylate aminotransferase and glutathione S-transferase κ1 show no, or almost no, import when used in these assays. A possible reason for this may be the weak PTS1 they harbor 39 , which probably translates into short half-lives of their complexes with PEX5. Thus, a preincubation step with recombinant PEX5 before in vitro import, the strategy used here for SCPx, does not really improve their import yields because the complexes probably dissociate within a few seconds after starting the import assay.
The in vitro system described here can be used in biochemical complementation assays to identify and/or characterize components of the peroxisomal PIM other than just PEX5 and PEX7 (e.g., the ubiquitin conjugation enzymes E2D1/2/3 (ref. 33) , the deubiquitinase USP9X 30 and the adaptor protein AWP1 (ref. 40) ). However, because organelles from wild-type rat/mouse are used in this protocol, only soluble components can be studied in this manner, as only these can be removed from or added to the organelle suspension. Clearly, for the membrane-embedded components of the peroxisomal PIM, other approaches will have to be used.
Box 2 | Synthesis of radiolabeled proteins • tIMInG ~ 2 h for in vitro synthesis, plus 3-6 h for SDS-PAGE/Western blotting/autoradiography analysis
! cautIon Wear gloves and follow appropriate laboratory procedures while handling radioactive material.  crItIcal To avoid RNase contamination, microtubes and pipette tips should be RNase-free. Reserve a new box/package of these materials for this purpose and always handle them while wearing clean gloves. 1. Assemble a 50-µl TNT T7 Quick Coupled Transcription/Translation reaction mixture according to the manufacturer's instructions and synthesize the 35 S-labeled reporter protein.  crItIcal step Some PTS1 proteins (e.g., catalase, acyl-CoA oxidase 1 and urate oxidase) have been shown to homo-oligomerize during in vitro synthesis, yielding protease-resistant species. Addition of recombinant PEX5L (0.1-1 µM) at the beginning of the synthesis reaction prevents this, and yields soluble, protease-sensitive monomeric species, which, in at least two cases, are much better import substrates than the corresponding oligomeric forms 14, 50 . Alternatively, decrease the suggested time of protein synthesis from 90 min to 30-60 min (homo-oligomerization is concentration-and time-dependent). 2. Prepare aliquots of the RRL containing the 35 S-labeled reporter protein (e.g., 5-µl aliquots) and store them at −70 °C. Keep a 0.5-µl aliquot to check for correct protein synthesis.  pause poInt Aliquots can be stored at −70 °C for a few months (take into consideration the half-life of 35 S (87 d)). 3. Add 20 µl of Laemmli sample buffer 1× containing 100 mM DTT to the 0.5-µl aliquot saved above, incubate for 5 min at 90 °C with shaking and subject to SDS-PAGE. Load one lane of the gel with molecular-weight markers. 4. Subject the gel to western blotting/autoradiography, as described in Steps 14-17 of the main procedure. Expose the membrane to an X-ray film for 1-2 h, and develop the film. A strong signal corresponding to the 35 S-labeled protein should be visible on the autoradiograph.
MaterIals

REAGENTS
Male rat or mouse at 6-10 weeks of age, fasted overnight (e.g., specific pathogen-free Wistar Han rat (strain code: 273) or C57BL/6 mouse (strain code: 027) from Charles River) ! cautIon Experiments using rodents must conform to national and institutional regulations. The animals used here were handled in accordance with the protocols approved by the IBMC Animal Ethics Committee (CEA-Comissão de Ética Animal Other recombinant proteins may be produced as well. A useful one for the PEX5-centered in vitro assays is the glutathione S-transferase-ubiquitin fusion protein (GST-Ub), a dominant-negative version of ubiquitin 21 (table 1) . This protein is expressed in large amounts in E. coli BL21(DE3) and purified using glutathione-sepharose 4B beads (GE Healthcare) 64 . Other recombinant proteins that may be useful in some experiments are as follows: ∆C1PEX5S (equivalent to ∆C1PEX5L but derived from PEX5S; used as a negative control for ∆C1PEX5L 26 ); matPHYH (the mature form of human phytanoyl-CoA hydroxylase; used as a negative control for prePHYH 3 ); and PEX19 (a peroxin with no role in the PIM), which is sometimes used as a negative control for histidine-tagged recombinant proteins 65 . The four recombinant proteins listed above are also N-terminally histidine-tagged proteins. All are obtained in large amounts from E. coli transformed with the corresponding expression plasmids. With the exception of histidine-tagged PEX5L, which requires an extra chromatography step (e.g., anionic exchange on a Bio-Scale Mini Macro-Prep High Q column (Bio-Rad) using a 300-800 mM NaCl gradient), all other histidine-tagged recombinant proteins are obtained with adequate purity (>90%) after a single immobilized metal-affinity chromatography step using a nickel-nitrilotriacetic acid matrix. Note that all these recombinant proteins are soluble and stable when handled as suggested here. However, if necessary, their monodispersity can be easily assessed by size-exclusion chromatography or native-PAGE 13, 50 . Below, a general protein purification protocol, as well as a buffer exchange procedure for −70 °C storage, is provided.
Inoculate a Petri dish containing LB/agar plus the appropriate antibiotic(s) with E. coli cells harboring the relevant expression plasmid. Incubate overnight at 37 °C. 2. Pick a colony and use it to inoculate 25 ml of LB + antibiotic(s)
. Grow this starter culture at 37 °C with shaking overnight. 3. The following day, dilute the starter culture with 500 ml of LB + antibiotic(s). Grow the culture at 37 °C with shaking for 1.5-2 h, or until OD 600 = 0.6-0.8. 4. Induce protein expression with 500 µl of 1 M IPTG (1 mM final concentration). Keep the culture at 37 °C with shaking for 3 h. 5. Centrifuge the culture at 4,500g, 4 °C, for 15 min to collect cells. Discard the supernatant.  pause poInt Cell pellets can be stored at −70 °C for several months. 6. Resuspend the cell pellet in 30 ml of lysis buffer. Use lysis buffer A for PEX5, ∆C1PEX5L, ∆C1PEX5S, NDPEX14 and PEX19, and lysis buffer B for prePHYH and matPHYH. 7. Disrupt the cells by sonication for ~4 min in 10-to 15-s pulses (10% output power, 40% duty cycle).  crItIcal step Ensure that the sample is always cold. Keep it on ice and pause sonication as needed. 8. Transfer the E. coli homogenate to a centrifuge tube (e.g., for rotor SS-34) and centrifuge the suspension at 12,000g at 4 °C for 20 min. Collect the clarified lysate and discard the pellet. 9. (Optional) This step is used only for purification of recombinant ∆C1PEX5L, ∆C1PEX5S and PEX19. Put the clarified lysate in a boiling water bath for 5 min. Cool it on ice for 5 min and centrifuge the suspension at 12,000g at 4 °C for 20 min. Discard the pellet.  crItIcal step This will denature and precipitate most E. coli proteins, leaving the largely natively unfolded ∆C1PEX5L, ∆C1PEX5S and PEX19 recombinant proteins in solution. Thus, sample complexity is markedly decreased, increasing the purity of the final protein preparation. 10. Add the clarified lysate to 1.5 ml (bed volume) of HIS-Select Nickel Affinity Gel beads that were previously washed two times with three volumes of ddH 2 O and equilibrated three times with three volumes of lysis buffer (minus DTT and PMSF). Incubate at 4 °C for 2 h with gentle agitation. 11. Spin down for 2 s at 600g, 4 °C, to collect beads. Discard the supernatant. 12. Add 15 ml of washing buffer A (for PEX5, ∆C1PEX5L, ∆C1PEX5S, NDPEX14 and PEX19) or washing buffer B (for prePHYH and matPHYH) to the beads. Mix by inverting the tube a few times and centrifuge as above. Discard the supernatant. Repeat this step twice. 13. Add 4.5 ml of elution buffer and incubate at 4 °C for 10 min with agitation. Spin down for 2 s at 600g, 4 °C, to collect the beads and recover the supernatant (containing the eluted protein). Repeat the elution step and pool the two elutions. 14. Use Vivaspin 2 Sample Concentrators to concentrate the eluted protein to ~200 µl. Dilute to 2 ml (final volume) with protein storage buffer and concentrate again to ~200 µl. Repeat this step three more times. 15. Collect the concentrated protein in an ice-cold microtube, and centrifuge for 20 min at 11,300g, 4 °C, to remove any agarose beads. Collect the supernatant and store 10-µl aliquots at −70 °C after flash-freezing them in liquid nitrogen.  pause poInt Aliquots that are kept at −70 °C and not subjected to multiple freeze-thaw cycles are stable up to 1 year. • 
mM Ubal
Ubal is generally purchased as a 1 mg/ml solution in 150 mM HCl (the actual concentration of Ubal may be lot-specific). Immediately before use, neutralize most of the HCl with 1 M NaOH (e.g., for a 10-µl aliquot of Ubal solution, add 1.4 µl of 1 M NaOH).  crItIcal Ubal is unstable at an alkaline pH; the partial neutralization strategy used here ensures that it will remain at a pH <7.0, and that its addition to the in vitro assays will have no impact on the pH. Import buffer 6× Import buffer 6× is 1.5 M sucrose, 300 mM KCl, 120 mM MOPS, pH 7.2, 18 µg/ml methionine and 18 mM MgCl 2 . Dissolve 5.1 g of sucrose in 1.2 ml of 1 M MOPS-KOH, pH 7.2, 1 ml of 3 M KCl and 90 µl of 2 M MgCl 2 , and adjust the volume to 10 ml with water (final volume). Store 250-µl aliquots at −20 °C. This buffer is stable for at least 1 year. Before use, supplement the 250-µl aliquot with 1.5 µl of 3 g/l methionine. SEM buffer SEM buffer is 0.25 M sucrose, 20 mM MOPS-KOH, pH 7.2, and 1 mM EDTA-NaOH, pH 8.0. Dissolve 21.4 g of sucrose in 100 ml of water. Add 5 ml of 1 M MOPS-KOH, pH 7.2, and 0.5 ml of 0.5 M EDTA-NaOH, pH 8.0, and make up to 250 ml with water. Store the solution at 4 °C; it is stable for several weeks. SEMK buffer SEMK buffer is SEM buffer supplemented with 80 mM KCl. Dissolve 21.4 g of sucrose in 100 ml of water. Add 5 ml of 1 M MOPS-KOH, pH 7.2, 6.67 ml of 3 M KCl, and 0.5 ml of 0.5 M EDTA-NaOH, pH 8.0, and make up the volume to 250 ml with water. Store the buffer at 4 °C; it is stable for several weeks. • Laemmli SDS-PAGE running buffer (e.g., Bio-Rad, cat. no. 1610732) Buffer for western blotting (e.g., Bio-Rad, cat. no. 1610734) Bacteria lysis buffer A Lysis buffer A is 50 mM Tris, pH 8.0, 150 mM NaCl, 1 mM DTT, 0.1% (wt/vol) TX-100, 50 µg/ml PMSF and 1:1,000 (vol/vol) of protease inhibitor cocktail. Mix 5 ml of 1 M Tris, pH 8.0, 3 ml of 5 M NaCl and 500 µl of 20% (wt/vol) TX-100. Make up the volume to 100 ml with water and store it at 4 °C. This solution is stable for several months. Immediately before use, supplement 30 ml of the buffer with 30 µl of 1 M DTT, 30 µl of 50 mg/ml PMSF and 30 µl of protease inhibitor cocktail. Bacteria lysis buffer B Lysis buffer B is 20 mM sodium phosphate buffer, pH 8.0, 500 mM NaCl, 0.1% (wt/vol) TX-100, 10 mM imidazole, 50 µg/ml PMSF and 1:1,000 (vol/vol) of protease inhibitor cocktail. Mix 4 ml of 0.5 M sodium phosphate buffer, pH 8.0, 10 ml of 5 M NaCl, 1 ml of 1 M imidazole and 500 µl of 20% (wt/vol) TX-100. Make up the volume to 100 ml with water and store the solution at 4 °C. This buffer is stable for several months. Before use, supplement 30 ml of the buffer with 30 µl of 50 mg/ml PMSF and 30 µl of protease inhibitor cocktail. Washing buffer A Washing buffer A is 50 mM sodium phosphate buffer, pH 8.0, and 150 mM NaCl. Mix 10 ml of 0.5 M sodium phosphate buffer, pH 8.0, with 3 ml of 5 M NaCl and make up the volume to 100 ml with water. Store it at 4 °C. This solution is stable for several months. Washing buffer B Washing buffer B is 50 mM sodium phosphate buffer, pH 8.0, and 500 mM NaCl. Mix 10 ml of 0.5 M sodium phosphate buffer, pH 8.0, with 10 ml of 5 M NaCl and make up the volume to 100 ml with water. Store it at 4 °C. This buffer is stable for several months. Elution buffer Elution buffer is 50 mM sodium phosphate buffer, pH 8.0, 150 mM NaCl, 250 mM imidazole and 1 mM DTT. Mix 1.5 ml of 0.5 M sodium phosphate buffer, pH 8.0, 450 µl of 5 M NaCl, 3.75 ml of 1 M imidazole and 15 µl of 1 M DTT, and make up the volume to 15 ml with water. Freshly prepare the buffer and keep it on ice. Protein storage buffer The protein storage buffer is 50 mM Tris, pH 8.0, 150 mM NaCl, 1 mM EDTA-NaOH, pH 8.0, and 1 mM DTT. Mix 5 ml of 1 M Tris, pH 8.0, 3 ml of 5 M NaCl and 200 µl of 0.5 M EDTA-NaOH, pH 8.0, and make up the volume to 100 ml with water. Store the buffer at 4 °C. It is stable for several months. Before use, supplement 20 ml of the buffer with 20 µl of DTT 1 M and keep it on ice. 35 S-labeled reporter protein (e.g., PEX5L, PEX7, pre-thiolase or SCPx) Synthesize using the TNT T7 Quick Coupled Transcription/ Translation System per the manufacturer's instructions (Box 2). Aliquots can be stored at −70 °C for a few months.
• • proceDure In vitro import(/export) protocol • tIMInG 3-5 h 1| Rapidly thaw, while gently mixing, an aliquot of the RRL containing the relevant 35 S-labeled reporter protein (PEX5, PEX7, pre-thiolase or SCPx; see box 2). Immediately put the solution on ice and dilute it according to the following table. The volumes provided are for two import(/export) reactions. Scale up volumes as needed for a greater number of reactions.  crItIcal step PNS should be quickly thawed in your hands while gently tapping the tube several times. Once thawed, place it on ice and use it immediately. Any thawed PNS that is not used should be discarded.
3| (Optional) Prime the PNS for import by incubating it for 5 min at 37 °C.  crItIcal step This is a mandatory step only when working with experimental conditions that block export of PEX5 from the DTM (e.g., assays containing AMP-PNP, GST-Ub or apyrase; 
After mixing these components, add:
Protein storage buffer --0.9 -0.9 -0.9 - 14| Transfer the proteins from the gel onto a nitrocellulose membrane (western blotting) using a standard semidry apparatus.
15|
Stain the membrane with the Ponceau S solution for 1 min. Destain with a large volume of water for a few seconds until the membrane (but not the protein bands) is almost white. ! cautIon The Ponceau S solution contains TCA. It is very corrosive. Handle it with care.  crItIcal step Check that protein loadings were as planned and that samples were not degraded during processing/ analysis. ? troublesHootInG 16| Place the Ponceau S-stained membrane in a completely transparent plastic cover (e.g., a transparent sheet protector) and make a digital record of it using a standard computer scanner or any other high-resolution device.
17| Mark the membrane with small radioactive ink dots alongside the molecular-weight markers. Dry the membrane using a hair dryer.  crItIcal step The radioactive dye will help with aligning the film with the Ponceau S-stained membrane. Dry the membrane slowly, keeping the hair dryer 10-20 cm away from it. Nitrocellulose is an explosive and it will burn completely if heated too much! On the other hand, note that if the membrane is not completely dried, it will stick to the X-ray film.
18|
Expose the membrane to an X-ray film overnight in an exposure cassette. 
19|
antIcIpateD results
The protocol detailed above describes the basic configuration of organelle-based in vitro import assays using as reporter proteins either radiolabeled peroxisomal matrix proteins (containing PTS1 or PTS2) or the corresponding shuttling receptors (PEX5 and PEX5L.PEX7). All assays include a suitable negative control sample to attest to the specificity of the experiments. Figure 2a shows a PEX5-centered in vitro import assay performed in the presence of Ubal (table 1) and either ATP or the nonhydrolyzable analog AMP-PNP. The experiment clearly shows that in the presence of AMP-PNP only organelle-associated PEX5 is mono-ubiquitinated. Substituting ATP for AMP-PNP leads to the appearance of mono-ubiquitinated PEX5 in the cytosolic fraction of the assays, reflecting export of DTM-embedded Ub-PEX5 into the cytosol, a process catalyzed by the ATP-dependent mechanoenzymes PEX1 and PEX6. The relationship between organelle-associated Ub-PEX5 and soluble Ub-PEX5 can be easily confirmed by performing a two-step import/export assay, in which organelles from an AMP-PNPcontaining assay are isolated by centrifugation, resuspended in import buffer and incubated in the presence of ATP 30 . Figure 2b shows that PEX5 is indeed covalently modified by a ubiquitin molecule; addition of the ubiquitin analog GST-Ub to the assay increases the molecular mass of the modified PEX5 species by ca. 30 kDa, the molecular mass of GST. Finally, the fact that mono-ubiquitinated PEX5 is no longer detected when samples are treated with thiol-containing reagents before SDS-PAGE analysis indicates that the ubiquitin is linked to PEX5 through a thioester bond. Identical in vitro assays performed with 35 S-labeled PEX5(C11K) and PEX5(C11A) showed that cysteine 11 of PEX5 is the ubiquitinated residue 23 . (a) PEX5-centered in vitro import assay: export of mono-ubiquitinated PEX5 is an ATP-dependent step. Radiolabeled PEX5L was subjected to in vitro import reactions in the presence of Ubal and either ATP or AMP-PNP. After incubation, NEM-treated mixtures were centrifuged to separate organelles (P) from supernatants (S). Samples (derived from 100 µg of PNS protein) were then subjected to SDS-PAGE under nonreducing conditions. The membrane was probed with anti-PEX14 (a peroxisomal membrane protein) and anti-α-tubulin (a cytosolic protein). Lane I, 10% of the radiolabeled protein used in the total reactions. The Ponceau S-stained membrane is also shown. (b) PEX5 is mono-ubiquitinated at a cysteine residue. Radiolabeled PEX5L was incubated with a PNS in import buffer supplemented with AMP-PNP and either ubiquitin (Ub) or GST-ubiquitin (GST-Ub). NEM-treated organelles were then isolated and analyzed under nonreducing (−DTT) and reducing conditions (+DTT) by SDS-PAGE/western blotting/autoradiography. Lane I, 25% of the radiolabeled protein used in each assay. The Ponceau S-stained membrane is shown. (c) In vitro import of radiolabeled SCPx. Radiolabeled SCPx was subjected to in vitro import reactions in the presence of ATP and in the absence (lane 1) or presence of recombinant PEX5L (lanes 2-5). PEX5L was either added after the final reaction was assembled (lane 2) or preincubated with radiolabeled SCPx included in the lysate mix (lanes 3-5). Where indicated, NDPEX14 or PEX19 (a protein involved in a different aspect of peroxisome biogenesis 49 ) was included in the reactions (lanes 4 and 5, respectively). PK-treated organelles were subjected to SDS-PAGE/western blotting/autoradiography. Lanes I 1 and I 2 , 10% of the radiolabeled protein used in the assays shown in lanes 1 and 2, and lanes 3-5, respectively. To assess protein loadings, the membrane was probed with anti-catalase (a peroxisomal matrix protein). The Ponceau S-stained membrane is also shown. (d) In vitro import of radiolabeled PEX7 and pre-thiolase. Radiolabeled PEX7 and pre-thiolase (preThiol) were subjected to in vitro import reactions in the absence (−) or presence (+) of the indicated recombinant proteins. Pronase-treated organelles were then analyzed by SDS-PAGE/western blotting/autoradiography. matThiol, mature form of thiolase. Lane I, 5% of the radiolabeled proteins used in the assays. To assess protein loadings, the membrane was probed with anti-catalase. The Ponceau S-stained membrane is also shown. Figure 2c shows the typical results of the PTS1-centered in vitro assay using 35 S-labeled SCPx as the reporter protein. Note how import of SCPx is almost completely dependent on the preincubation step with recombinant PEX5-a chemically identical assay, but one in which the preincubation step was omitted, shows essentially no protease-protected SCPx (compare lanes 2 and 3). To demonstrate that the protease-resistant radiolabeled SCPx reflects authentic peroxisomal import, one control reaction was performed in the presence of NDPEX14. This recombinant protein binds to PEX5 and inhibits the PEX5-mediated import of SCPx (compare lane 4 with lane 5). The complete protease-treated import reaction (i.e., the organelle suspension obtained after Step 6B(ii) of the protocol) can also be subjected to Nycodenz gradient centrifugation to demonstrate that the reporter protein co-sediments with pure peroxisomes 26, 27 . Figure 2d shows the result of an in vitro import assay in which both 35 S-pre-thiolase, a PTS2 protein, and 35 S-PEX7 were used as reporter proteins. Note the marked increase in yields when recombinant ∆C1PEX5L is added to the assays (compare lanes 1 and 3) . Note also that a fraction of protease-protected 35 S-labeled pre-thiolase was converted into a faster migrating species (lanes 3 and 5) . This reflects processing of the precursor protein into its mature form, a relatively fast event in vivo and in vitro 26, 42 . Some PTS1 proteins (e.g., acyl-CoA oxidase 1 and SCPx) also undergo processing at the peroxisome matrix. However, these events are much slower, requiring many hours to be detected in vivo [42] [43] [44] . Thus, they are barely detected in in vitro assays.
The amount of organelle-associated protease-resistant 35 S-labeled PEX7 in these assays can be further increased by supplementing the import reaction with a recombinant PTS2 protein, in this case prePHYH (Fig 2d, compare lanes 3 and 4) . As expected, in the presence of recombinant prePHYH, but not mature PHYH (matPHYH) lacking PTS2, protease-resistant 35 S-pre-thiolase is no longer detected (Fig. 2d , compare lanes 4 and 5), reflecting competition with the more abundant recombinant PTS2 protein. Again, NDPEX14 completely blocks entry of 35 S-PEX7 into the organelle (compare lane 6 with lane 4). In the assay shown in lane 2, recombinant ∆C1PEX5S was used instead of ∆C1PEX5L. These two recombinant proteins are almost identical, except that ∆C1PEX5S lacks an internal 37-amino acid domain present in ∆C1PEX5L, which contains the PEX7-binding domain. As expected, neither reporter protein acquired a protease-protected status under these conditions, in agreement with the fact that only the large isoform of PEX5 is competent in the PTS2-mediated protein import pathway 45 .
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